Table 4.
Incidence of nausea and vomiting after exposure to non-ionic iodinated contrast media from representative publications where the incidence could be extracted
| Authors | Year | Country | Patient collection | Iodinated contrast media | Incidence | |
| Nausea | Vomiting | |||||
| Katayama et al5 | 1990 | Japan | Retrospective | Iopamidol, Iohexol | 1.04% (1749/168363) | 0.36% (614/168363) |
| Oowaki et al | 1994 | Japan | Unknown | Unknown | 1.4%a (17/1241) | |
| Federle et al16 | 1998 | USA | Prospective | Ioversol | 1.99% (9/452) | 0% (0/452) |
| Nagamoto et al17 | 2006 | Japan | Prospective | Iopamidol | 0.9% (8/940) | 0% (0/940) |
| Wendt-Nordahl et al18 | 2006 | Germany | Prospective (PMS) | Iobitridol | 0.3% | <0.1% |
| Vogl et al19 | 2006 | Germany | Prospective (PMS) | Iobitridol | 0.24% (127/52057) | 0.09% (45/52057) |
| Vijayalakshmi et al20 | 2007 | United Kingdom | Prospective | Iopamidol, Iomeprol | 0.55% (11/1985) | 0.40% (8/1985) |
| Gomi et al21 | 2010 | Japan | Prospective | Iopromide, Iomeprol, Iopamidol, Iohexol, Ioversol |
0.003%a,b (27/8931) | |
| Häussler et al22 | 2010 | Germany | Prospective (PMS) | Iodixanol | 0.12% (11/9515) | 0.08% (8/9515) |
| Maurer et al8 | 2011 | Germany | Prospective (PMS) | Iobitridol | 0.20% (315/160639) | 0.06% (89/160639) |
| Palkowitsch et al9 | 2014 | USA, Europe, Africa, Asia | Prospective (including PMS) | Iopromide | 0.52%a (689/132012) | |
| Zhang et al23 | 2014 | China | Prospective (PMS) | Iodixanol | 0.13% (27/20185) | 0.008% (16/20185) |
| Li et al24 | 2015 | China | Retrospective | Iopromide, Iodixanol, Iopamidol, Iohexol, loversol |
0.05% (51/109255) | 0.006% (7/109255) |
PMS, post-marketing surveillance.
Data in parenthesis indicates the number of patients.
a
Incidences of nausea and vomiting were not separable.
b
The incidence of nausea and vomiting which required medical treatment.
c
Study populations were suspected to be partly overlapped.